Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Promoting excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Riccardo Cappato,
Prof. Christoph Bode,
By Riccardo Cappato, FESC (San Donato Milanese, Italy)View Discussant report
Read the press releaseOpen the PresentationWatch the Webcast
List of Authors:
Riccardo Cappato 1, Michael D Ezekowitz 2, Allan L Klein 3, A. John Camm 4, Chang-Sheng Ma 5, Jean-Yves Le Heuzey 6, Mario Talajic 7, Maurício Scanavacca 8, Panos E. Vardas 9, Paulus Kirchhof 10, Melanie Hemmrich 11, Vivian Lanius 12, Isabelle Ling Meng 11, Peter Wildgoose 13, Martin van Eickels 11, Stefan H. Hohnloser 14, on behalf of the X-VeRT Investigators
AIMSX-VeRT is the first prospective randomized trial of a novel oral anticoagulant in patients with atrial fibrillation undergoing elective cardioversion.METHODS and RESULTSWe assigned 1504 patients to rivaroxaban (20 mg once daily, 15mg if creatinine clearance was between 30 and 49 mL/min) or dose-adjusted vitamin K antagonists (VKAs) in a 2:1 ratio. Investigators selected either an early (target period of 1–5 days after randomization) or delayed (3–8 weeks) cardioversion strategy. The primary efficacy outcome was the composite of stroke, transient ischaemic attack, peripheral embolism, myocardial infarction and cardiovascular death. The primary safety outcome was major bleeding. The primary efficacy outcome occurred in 5 (2 strokes) of 978 patients (0.51%) in the rivaroxaban group and in 5 (2 strokes) of 492 patients (1.02%) in the VKA group (risk ratio 0.50; 95% confidence interval [CI], 0.15–1.73). In the rivaroxaban group, 4 patients experienced primary efficacy events following early cardioversion (0.71%) and 1 following delayed cardioversion (0.24%). In the VKA group, 3 patients had primary efficacy events following early cardioversion (1.08%) and 2 following delayed cardioversion (0.93%). Rivaroxaban was associated with a significantly shorter time to cardioversion compared with VKAs (P < 0.001).Major bleeding occurred in 6 patients (0.6%) in the rivaroxaban group and 4 patients (0.8%) in the VKA group (risk ratio 0.76; 95% CI, 0.21–2.67).CONCLUSIONOral rivaroxaban appears to be an effective and safe alternative to VKAs and may allow prompter cardioversion.
Clinicaltrials.gov ID: NCT01674647
By Christoph Bode, FESC (Freiburg, Germany)See Presenter abstract
Open the presentationWatch the Webcast
Hot Line: Coronary artery disease and atrial fibrillation